What division makes the biggest profits for Roche group of companies?

Would that be Genentech?

 

The senior leadership team

 

Oncology or rare I think .

 

most pharma companies don't want anyone to know how profitable individual drugs are, but in this case, US Rituxan is shared with Biogen (fka Idec), who reports revenue and profit in their SEC filings (under "CD20 collaboration"). The US Rituxan operating margin (after Cost of Goods, sales, marketing, and some allocated overhead costs) is consistently >80% and is then split roughly evenly between the two companies. This is a long way of answering your question - the most profitable division by far is the US oncology business and the "Big 3" (Rituxan, Herceptin, Avastin)... for those in the industry though, the only thing really shocking about this is that Rituxan was never tax-planned so is one of the few drugs with US-based IP and still paying a 35% tax rate.

 

This makes complete sense. How much longer before the patents expire on these big 3...? Not too long I presume?

Thanks.